Cited by 1,233Multiple Myeloma Research and TreatmentsBone health and treatmentsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Open access

Weber, Donna M., Chen, Christine, Niesvizky, Ruben, Wang, Michael, Belch, Andrew, Stadtmauer, Edward A., Siegel, David, Borrello, Ivan, Rajkumar, S. Vincent, Chanan-Khan, Asher Alban, Lonial, Sagar, Yu, Zhinuan, Patin, John, Olesnyckyj, Marta, Zeldis, Jerome B., Knight, Robert D.·2007·New England Journal of Medicine

DOI 10.1056/nejmoa070596

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma. METHODS: Patients in the United States and Canada who had received at least one previous therapy for multiple myeloma but who required additional treatment were randomly assigned to receive either 25 mg of lenalidomide or placebo on days 1 to 21 of a 28-day cycle. Both groups also received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles. After the fourth cycle, 40 mg of dexamethasone was administered only on days 1 to 4. Safety, clinical response, time to progression, and overall survival were assessed. RESULTS: We assigned 177 patients to the lenalidomide group and 176 to the placebo group. Complete, near-complete, or partial responses occurred in 108 patients (61.0%) in the lenalidomide group and in 35 patients (19.9%) in the placebo group (P<0.001); complete responses occurred in 14.1% and 0.6%, respectively (P<0.001). The median time to progression was 11.1 months in the lenalidomide group and 4.7 months in the placebo group (P<0.001). Median overall survival times in the two groups were 29.6 months and 20.2 months, respectively (P<0.001). Grade 3 or 4 adverse events were reported in 85.3% of the lenalidomide group and in 73.1% of the placebo group; these events resulted in study discontinuation in 19.8% and 10.2%, respectively. Grade 3 or 4 neutropenia and venous thromboembolism were more common in the lenalidomide group than in the placebo group (41.2% vs. 4.6% and 14.7% vs. 3.4%, respectively; P<0.001 for both comparisons). CONCLUSIONS: Lenalidomide plus dexamethasone is superior to placebo plus dexamethasone in patients with relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00056160 [ClinicalTrials.gov].).

Integrity signals

Registry

Crossref · 10.1056/nejmoa070596

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citation
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citation
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Self-citation
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
Bladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Hideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citation
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citation
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K. B., & Alexanian, R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 565
Self-citation
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citation
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Self-citation

Flagged first, then by citations

Show all 13 references

Sorted by citations

Items 501–600 of 1,000

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies
Hájek, R., Jarkovský, J., Maisnar, V., Pour, L., Špıčka, I., Minařík, J., Gregora, E., Kessler, P., Sýkora, M., Fraňková, H., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.04.003 · Cited by 24
Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
Luo, X., Du, X., Li, J.-L., Liu, X., & Meng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s166640 · Cited by 23
Therapy of Relapsed and Refractory Multiple Myeloma
Moehler, T. M., & Goldschmidt, H. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_11 · Cited by 24
Molecular and cellular effects of multi‐targeted cyclin‐dependent kinase inhibition in myeloma: biological and clinical implications
McMillin, D. W., Delmore, J. E., Negri, J. M., Buon, L., Jacobs, H. M., Laubach, J. P., Jakubı́ková, J., Ooi, M. G. M., Hayden, P. J., Schlossman, R. L., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08427.x · Cited by 24
Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future
Waxman, A. J., Kuehl, M. W., Balakumaran, A., Weiss, B. M., & Landgren, O. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.053 · Cited by 25
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
Laubach, J. P., Schlossman, R. L., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2011) · Expert Review of Hematology · doi:10.1586/ehm.10.83 · Cited by 24
Changing paradigms in the treatment of multiple myeloma
Bladé, J., & Rosiñol, L. (2009) · Haematologica · doi:10.3324/haematol.2008.002766 · Cited by 23
Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
Einsele, H., & Schreder, M. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716657993 · Cited by 24
A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma
Ri, M., Suzuki, K., Iida, S., Hatake, K., Chou, T., Taniwaki, M., Watanabe, N., & Tsukamoto, T. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9567-17 · Cited by 24
Emerging Immune Targets for the Treatment of Multiple Myeloma
Sohail, A., Mushtaq, A., Iftikhar, A., Warraich, Z., Kurtin, S. E., Tenneti, P., McBride, A., & Anwer, F. (2018) · Immunotherapy · doi:10.2217/imt-2017-0136 · Cited by 24
Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma
Huskey, J. L., Heilman, R. L., Khamash, H. A., & Fonseca, R. (2018) · Transplantation · doi:10.1097/tp.0000000000002449 · Cited by 24
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Klobuch, S., Thomas, S., Pukrop, T., Hackl, C., Herr, W., Ghibelli, L., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01357 · Cited by 24
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
Lee, S., Lim, J., Ryu, D., Kim, T., Yoon, J., Cho, B., Eom, K., Kim, Y., Kim, H., Lee, S., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1861-2 · Cited by 25
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Miguel, J. F. S., Einsele, H., & Moreau, P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0413-7 · Cited by 25
Lenalidomide and thalidomide in the treatment of chronic pain
Asher, C., & Furnish, T. J. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.775242 · Cited by 23
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
Dimopoulos, M. A., Hussein, M. A., Swern, A. S., & Weber, D. (2011) · Leukemia · doi:10.1038/leu.2011.126 · Cited by 23
Self-citation
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
Sanborn, S. L., Gibbons, J., Krishnamurthi, S., Brell, J. M., Dowlati, A., Bokar, J. A., Nock, C. J., Horvath, N., Bako, J., Remick, S. C., et al. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9200-x · Cited by 23
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment
Bridoux, F., Chen, N., Moreau, S., Arnulf, B., Moumas, É., Abraham, J., Desport, É., Jaccard, A., & Fermand, J. P. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3068-9 · Cited by 23
Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation
Liu, A., Li, S., Donnenberg, V. S., Fu, J., Gollin, S. M., Ma, H., Lu, C., Stolz, D. B., Mapara, M. Y., Monaghan, S. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188227 · Cited by 25
Plasma Cell Tumors
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Advances in Supportive Care for Multiple Myeloma
Raje, N. S., Yee, A. J., & Roodman, G. D. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0055 · Cited by 22
CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma
Benson, D. M., & Byrd, J. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4061 · Cited by 23
Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo
Jinesh, G. G., Lee, E. K., Tran, J., & Kamat, A. M. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.05.007 · Cited by 22
Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
Hesterberg, R. S., Beatty, M. S., Han, Y., Fernandez, M. R., Akuffo, A. A., Goodheart, W. E., Yang, C., Chang, S., Colin, C., Alontaga, A. Y., et al. (2020) · Blood · doi:10.1182/blood.2019003257 · Cited by 22
Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
Reece, D. E., Kouroukis, C. T., LeBlanc, R., Sébag, M., Song, K., & Ashkenas, J. (2012) · Advances in Hematology · doi:10.1155/2012/621958 · Cited by 23
Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs
Ocio, E. M., Mateos, M., & Miguel, J. F. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.691164 · Cited by 22
Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial
Redman, M. W., Goldman, B. H., LeBlanc, M. L., Schott, A. F., & Baker, L. H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2939 · Cited by 23
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
Boudreault, J., Touzeau, C., & Moreau, P. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1285694 · Cited by 22
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma
Lancman, G., Lozada, K. S., Athar, N., Jacobs, S. E., Doucette, J. T., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.026 · Cited by 22
Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
Biran, N., Jagannath, S., & Chari, A. (2013) · PubMed · Cited by 22
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
Chanan-Khan, A. A., Miller, K. C., Musial, L., Padmanabhan, S., Yu, J., Ailawadhi, S., Sher, T., Mohr, A., Bernstein, Z. P., Barcos, M. P., et al. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902912460 · Cited by 22
Self-citation
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
Richardson, P. G. G. (2009) · Core evidence · doi:10.2147/ce.s6002 · Cited by 22
NMDA Receptor Subunit NR2b: Effects on LH Release and GnRH Gene Expression in Young and Middle-Aged Female Rats, with Modulation by Estradiol
Maffucci, J. A., Walker, D. M., Ikegami, A., Woller, M. J., & Gore, A. C. (2007) · Neuroendocrinology · doi:10.1159/000111136 · Cited by 22
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma
Chanan-Khan, A. A., Lonial, S., Weber, D., Borrello, I., Foà, R., Hellmann, A. R., Dimopoulos, M. A., Swern, A. S., & Knight, R. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1125-7 · Cited by 21
Self-citation
Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program
Kneppers, E., Lokhorst, H. M., Eeltink, C., Huls, G. A., Kersten, M. J., Koedam, J., Minnema, M. C., van Oers, M. H. J., Raymakers, R. A. P., Schaafsma, M. R., et al. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.020 · Cited by 21
Lenalidomide in patients with chemotherapy‐induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single‐centre prospective study
Briani, C., Torre, C. D., Campagnolo, M., Lucchetta, M., Berno, T., Candiotto, L., Padua, L., Ermani, M., Cavaletti, G., & Zambello, R. (2013) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12002 · Cited by 22
Recent Advances in the Pathogenesis and Management of Cast Nephropathy (Myeloma Kidney)
Stringer, S. J., Basnayake, K., Hutchison, C. A., & Cockwell, P. (2011) · Bone Marrow Research · doi:10.1155/2011/493697 · Cited by 21
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma
Mark, T. M., Coleman, M., & Niesvizky, R. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.02.008 · Cited by 21
Self-citation
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis
Boyle, E. M., Fouquet, G., Manier, S., Gauthier, J., Noel, M. P., Borie, C., Facon, T. T. F., Elalamy, I., & Leleu, X. P. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.52 · Cited by 21
Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019
Giannopoulos, K., Jamroziak, K., Usnarska‐Zubkiewicz, L., Dytfeld, D., Jurczyszyn, A. J., Walewski, J. A., Lech‐Marańda, E., Walter‐Croneck, A., Pieńkowska‐Grela, B., Wróbel, T., et al. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0024 · Cited by 22
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes
Palumbo, A. P., Freeman, J., Weiss, L., & Fenaux, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.619975 · Cited by 21
Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma
Harada, T., Ozaki, S., Oda, A., Fujii, S., Nakamura, S., Miki, H., Kagawa, K., Takeuchi, K., Matsumoto, T., & Abe, M. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1321-0 · Cited by 21
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients
Alegre, A. M., Aguado, B., Giraldo, P., Ríos, E., Cánovas, A., Ibáñez, Á., Castillo, I., Hernández, M., Oriol, A., Palomera, L., et al. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0785-z · Cited by 22
Quantitative Measures of Physical Functioning After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Feasibility Study
Tuchman, S. A., Lane, A. R., Hornsby, W., Bishop, C. E., Thomas, S. M., Herndon, J. E., Long, G. D., Gasparetto, C., & Jones, L. W. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.09.002 · Cited by 21
Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study
Petrucci, M. T., Calabrese, E., Levi, A., Federico, V., Ceccolini, M., Rizzi, R., Gozzetti, A., Falco, P., Lazzaro, C. R., Martelli, E., et al. (2013) · Tumori Journal · doi:10.1177/030089161309900434 · Cited by 20
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma
Qiao, S.-K., Guo, X., Ren, J., & Ren, H. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.156134 · Cited by 23
Lenalidomide in multiple myeloma: current experimental and clinical data
Cives, M., Milano, A., Dammacco, F., & Silvestris, F. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01735.x · Cited by 20
Multiple myeloma
Eshaghian, S., & Berenson, J. R. (2012) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283565c56 · Cited by 20
Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)
Wang, M., Delasalle, K. B., Giralt, S., & Alexanian, R. (2010) · Hematology · doi:10.1179/102453310x12583347010133 · Cited by 20
Self-citation
Advances in multiple myeloma therapy during two past decades
Špıčka, I. (2014) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.05.005 · Cited by 20
Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
Pozzi, S., Bari, A., Pecherstorfer, M., & Vallet, S. (2021) · Cancers · doi:10.3390/cancers13194978 · Cited by 20
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study
Rosovsky, R. P. G., Hong, F., Tocco, D., Connell, B., Mitsiades, C. S., Schlossman, R. L., Ghobrial, I. M., Lockridge, L., Warren, D. L., Bradwin, G., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12152 · Cited by 20
Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QT c Intervals in the Thorough QT c Study Conducted in Healthy Men
Chen, N., Ye, Y., Liu, L., Reyes, J. F., Assaf, M. S., Kasserra, C., Zhou, S. Y., & Palmisano, M. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12081 · Cited by 20
Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
Siena, S., Cutsem, E. V., Li, M., Jungnelius, U., Romano, A., Beck, R. E., Bencardino, K. B., Élez, E., Prenen, H., Sanchis, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062264 · Cited by 21
Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis
Clave, E., Douay, C., Coman, T., Busson, M., Bompoint, C., Moins‐Teisserenc, H., Glauzy, S., Carmagnat, M., Gorin, N. C., Toubert, A., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.865182 · Cited by 21
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial
Mey, U., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T. N., Jehner, P., Rauh, J., Taverna, C., Schmid, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14481 · Cited by 22
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
Katodritou, E., Kyrtsonis, M., Delimpasi, S., Kyriakou, D. S., Symeonidis, A. S., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, Α., Kioumi, A., Zikos, P., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3361-2 · Cited by 20
How I treat elderly patients with plasma cell dyscrasias
Gavriatopoulou, M., Fotiou, D., Ntanasis‐Stathopoulos, I., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2018) · Aging · doi:10.18632/aging.101707 · Cited by 20
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial
Schey, S., Brown, S., Tillotson, A., Yong, K., Williams, C. D., Davies, F. E., Morgan, G. J., Cavenagh, J. D., Cook, G., Cook, M. A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13435 · Cited by 20
Pomalidomide: A new IMiD with remarkable activity in both multiple myeloma and myelofibrosis
Lacy, M. Q., & Rajkumar, S. V. (2009) · American Journal of Hematology · doi:10.1002/ajh.21610 · Cited by 20
Self-citation
Targeted therapies for patients with germ cell tumors
Fenner, M. H., Beutel, G., & Grünwald, V. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.511 · Cited by 20
The Era of Combination Therapy in Myeloma
Lonial, S., & Kaufman, J. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.6967 · Cited by 19
Self-citation
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs
Festuccia, M. B., Martino, M. V., Ferrando, F., Messina, G., Moscato, T., Fedele, R., Boccadoro, M., Giaccone, L., & Bruno, B. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036735 · Cited by 19
Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
Jiang, T., Su, H., Li, Y., Wu, Y., Ming, Y., Li, C., Fu, R., Feng, L., Li, Z., Li, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989032 · Cited by 21
Memory loss during lenalidomide treatment: a report on two cases
Rollin‐Sillaire, A., Delbeuck, X., Pollet, M., Mackowiak, M., Lenfant, P., Noël, M., Facon, T. T. F., Leleu, X. P., Pasquier, F., & Rhun, É. L. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-41 · Cited by 19
Phase I‐ II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
Reece, D. E., Masih‐Khan, E., Atenafu, E. G., Jimenez-Zepeda, V. H., Anglin, P., Chen, C. I., Kukreti, V., Mikhael, J. R., & Trudel, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.13100 · Cited by 19
Self-citation
Novel insights into the mechanism of action of lenalidomide
Semeraro, M., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28386 · Cited by 19
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Patriarca, F. F., Petrucci, M. T., Bringhen, S., Baldini, L., Caravita, T., Corradini, P., Corso, A., Raimondo, F. D., Falcone, A. P., Ferrara, F., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01179.x · Cited by 19
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies
Vallet, S., Witzens‐Harig, M., Jaeger, D., & Podar, K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656091 · Cited by 20
Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis
Malard, F., Harousseau, J., & Mohty, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.005 · Cited by 19
Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins
Magarotto, V., Salvini, M., Bonello, F., Bringhen, S., & Palumbo, A. P. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1102245 · Cited by 18
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Boyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 18
Self-citation
Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation
Blimark, C. H., Veskovski, L., Westin, J., Rödjer, S., Brune, M. L., Hjorth, M., Holmberg, E. C., Andersson, P., & Mellqvist, U. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01634.x · Cited by 18
The DAC system and associations with multiple myeloma
Ocio, E. M., & Miguel, J. F. S. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9589-x · Cited by 18
Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice
Castelli, R., Cannavò, A., Conforti, F., Grava, G., & Cortelezzi, A. (2012) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2012.658921 · Cited by 19
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma
Offidani, M., Corvatta, L., Polloni, C., Gentili, S., Mele, A., Rizzi, R., Catarini, M., Caraffa, P., Samorì, A., Blasi, N., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1217-0 · Cited by 18
IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.
Cheikh, J. E. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.026 · Cited by 18
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies
Morgan, G. J. (2010) · Blood Reviews · doi:10.1016/s0268-960x(10)70006-0 · Cited by 18
Anticancer Activity and Underlying Mechanism of Phytochemicals against Multiple Myeloma
Kang, B., Park, H., & Kim, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092302 · Cited by 18
Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database
Uno, S., Goto, R., Suzuki, K., Iwasaki, K., Takeshima, T., & Ohtsu, T. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1686870 · Cited by 18
Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma
Mynott, R. L., & Wallington-Beddoe, C. T. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00074 · Cited by 20
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
Royle, K., Coulson, A. B., Ramasamy, K., Cairns, D. A., Hockaday, A., Quezada, S. A., Drayson, M. T., Kaiser, M., Owen, R. G., Auner, H. W., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063037 · Cited by 17
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety
Party, T. K. M. M. W., Lee, S. S., Suh, C., Kim, B.-S., Chung, J.-S., Joo, Y., Ryoo, H.-M., Do, Y. R., Jin, J., Kang, H. J., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0943-z · Cited by 17
Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece
Fragoulakis, V., Maniadakis, N., Ψαλτοπούλου, Θ., & Kastritis, E. (2013) · Cancer Management and Research · doi:10.2147/cmar.s43373 · Cited by 18
Lenalidomide in Multiple Myeloma—A Practice Guideline
Chen, C., Baldassarre, F. G., Kanjeekal, S. M., Herst, J. A., Hicks, L. K., & Cheung, M. C. (2013) · Current Oncology · doi:10.3747/co.20.1252 · Cited by 19
Self-citation
Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
Duong, V. H., Komrokji, R. S., & List, A. F. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620711435659 · Cited by 20
A Benefit–Risk Analysis Approach to Capture Regulatory Decision‐Making: Multiple Myeloma
Raju, G. K. P., Gurumurthi, K., Domike, R., Kazandjian, D. G., Landgren, O., Blumenthal, G. M., Farrell, A. T., Pazdur, R., & Woodcock, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.871 · Cited by 19
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
Falk, I. J., Lund, J., Gréen, H., Gruber, A., Alici, E., Lauri, B., Blimark, C. H., Mellqvist, U., Swedin, A., Forsberg, K., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3481-8 · Cited by 18
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
Guglielmelli, T., Bringhen, S., Rrodhe, S., Gay, F., Cavallo, F., Berruti, A., Montefusco, V., Piro, E., Benevolo, G., Petrucci, M. T., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.026 · Cited by 17
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors
Harada, T., Ozaki, S., Oda, A., Tsuji, D., Ikegame, A., Iwasa, M., Udaka, K., Fujii, S., Nakamura, S., Miki, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083905 · Cited by 18
Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
Fatoki, R. A., Koehn, K., Kelkar, A. H., Hadidi, S. A., Mehra, N., Mian, H. S., Landgren, O., Kazandjian, D. G., Hoffman, J. E., Sborov, D. W., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00119 · Cited by 18
Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance
Kristinsson, S. Y., Björkholm, M., Schulman, S., & Landgren, O. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.002 · Cited by 17
Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
Bila, J., Sretenović, A., Jelicic, J., Tos̆ić, N., Glumac, I., Fekete, M. D., Antic, D. A., Todorović, M., Marković, O., Milojevic, Z., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.007 · Cited by 17
Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure
Alhuraiji, A., Naqvi, K., Huh, Y. O., Ho, C., Verstovšek, S., & Bose, P. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1264 · Cited by 17
Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia
Tochigi, T., Miyamoto, T., Hatakeyama, K., Sakoda, T., Ishihara, D., Irifune, H., Shima, T., Kato, K., Maeda, T., Ito, T., et al. (2020) · Blood · doi:10.1182/blood.2019003749 · Cited by 19
Management of the adverse effects of lenalidomide in multiple myeloma
González, A. P. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0104-8 · Cited by 18
Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial
Fonseca, R., & Rajkumar, S. V. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.046 · Cited by 16
Self-citation
Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma
Anwer, S., Collings, F., Trace, K., Sun, Y., & Sternberg, A. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12351 · Cited by 16
Lenalidomide, an antineoplastic drug, and its hemihydrate
Ravikumar, K., & Sridhar, B. (2009) · Acta Crystallographica Section C Crystal Structure Communications · doi:10.1107/s0108270109033642 · Cited by 17

Authors: Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J. B., & Knight, R. D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Princess Margaret Cancer Centre (CA)
Cross Cancer Institute (CA)
University of Pennsylvania (US)
Hackensack University Medical Center (US)
Sidney Kimmel Comprehensive Cancer Center (US)
Mayo Clinic (US)
Roswell Park Comprehensive Cancer Center (US)
Emory University (US)
Celgene (United States) (US)
ORCID: Chen, Christine
Wang, Michael
Belch, Andrew
Stadtmauer, Edward A.
Siegel, David
Borrello, Ivan
Rajkumar, S. Vincent
Chanan-Khan, Asher Alban
Lonial, Sagar
Zeldis, Jerome B.
Knight, Robert D.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-11-22
Volume: 357
Issue: 21
Pages: 2133-2142
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa070596
OpenAlex: W2021954218
Cited by: 1,233
References: 13
Citations by year: 2026: 5 · 2025: 10 · 2024: 14 · 2023: 36 · 2022: 41 · 2021: 35 · 2020: 31 · 2019: 46 · 2018: 57 · 2017: 69 · 2016: 83 · 2015: 74 · 2014: 77 · 2013: 126 · 2012: 111
FWCI: 62.27
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords: lenalidomide, dexamethasone, relapsed multiple myeloma, refractory multiple myeloma, immunomodulators, combination chemotherapy, complete response, time to progression, overall survival, neutropenia, venous thromboembolism, adverse events, North America, thalidomide analogues, treatment efficacy and safety
MeSH terms: Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Double-Blind Method, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks